TGF-β Blocking Combined with Photothermal Therapy Promote Tumor Targeted Migration and Long-term Antitumor Activity of CAR-T Cells

Overview

Journal Mater Today Bio

Specialty Biomedical Engineering

Date 2023 Apr 17

PMID 37063775

Authors

Yuxiang Tang

Weiqi Yao

Hang Hu

Wei Xiong

Heng Mei

Yu Hu

Affiliations

Soon will be listed here.

Abstract

TGF-β is widely existed in tumor microenvironment, taking part in tumorigenesis process including angiogenesis, cancer associated fibroblast (CAF) proliferation, and immunosuppression. It inhibited the activation, proliferation, migration and differentiation of T cells, in which way caused a limited therapeutic effects of chimeric antigen receptor T (CAR-T) towards solid tumor such as lymphoma. To targeted block TGF-β at tumor site, we take advantages of nano-techniques to deliver TGF-β inhibitors LY2157299 (LY) towards the tumor sites, in order to help achieve a improved and long-term functions of CAR-T towards lymphoma. Based on amphipathic hydroxyethyl starch-polycaprolactone (HES-PCL), LY and photosensitizer indocyanine green (ICG) were co-loaded in HES-PCL to achieve LY/ICG@HES-PCL nanoparticle. The enhanced function of CAR-T benefited from LY/ICG@HES-PCL were verified through lymphoma Raji cells in vitro and Nod scid gamma mice engrafted with the Raji cells in vivo. LY was targeted transported to tumor site and accelerated release by mild ICG photothermal. Chemokines CXCL9/10/11 at the tumor site relevant to CAR-T migration and chemokines receptor CXCR3 of CAR-T could be up-regulated by LY, thus facilitated the enhanced accumulation of CAR-T at lymphoma site. T effector memory cells differentiation could also be accelerated by LY/ICG@HES-PCL. Combined therapy of LY/ICG@HES-PCL and CAR-T achieved 2.4 times higher antitumor activity and 2.7 times higher relapse inhibiting rates than CAR-T alone within 15 days and 11 days, respectively. The results suggested that LY/ICG@HES-PCL facilitated the enhanced therapeutic index of CAR-T cells towards lymphoma simply and safely, it may be further potentiated applied for other solid tumors.

Citing Articles

The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts.

Huang Q, Ge Y, He Y, Wu J, Tong Y, Shang H Int J Nanomedicine. 2024; 19:3333-3365.

PMID: 38617796 PMC: 11012801. DOI: 10.2147/IJN.S447350.

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques.

Tang Y, Yang X, Hu H, Jiang H, Xiong W, Mei H Front Bioeng Biotechnol. 2024; 11:1320807.

PMID: 38312512 PMC: 10835794. DOI: 10.3389/fbioe.2023.1320807.

References

Yang Z, Grote D, Xiu B, Ziesmer S, Price-Troska T, Hodge L . TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia. 2014; 28(9):1872-84. PMC: 4145058. DOI: 10.1038/leu.2014.84. View

Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang X . Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res. 2016; 23(5):1156-1166. DOI: 10.1158/1078-0432.CCR-16-1365. View

Shao C, Li Z, Zhang C, Zhang W, He R, Xu J . Optical diagnostic imaging and therapy for thyroid cancer. Mater Today Bio. 2022; 17:100441. PMC: 9640994. DOI: 10.1016/j.mtbio.2022.100441. View

Westin J, Kersten M, Salles G, Abramson J, Schuster S, Locke F . Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021; 96(10):1295-1312. PMC: 9290945. DOI: 10.1002/ajh.26301. View

Manivasagan P, Joe A, Han H, Thambi T, Selvaraj M, Chidambaram K . Recent advances in multifunctional nanomaterials for photothermal-enhanced Fenton-based chemodynamic tumor therapy. Mater Today Bio. 2022; 13:100197. PMC: 8753377. DOI: 10.1016/j.mtbio.2021.100197. View

Mikucki M, Fisher D, Matsuzaki J, Skitzki J, Gaulin N, Muhitch J . Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015; 6:7458. PMC: 4605273. DOI: 10.1038/ncomms8458. View

Savoldo B, Ramos C, Liu E, Mims M, Keating M, Carrum G . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011; 121(5):1822-6. PMC: 3083795. DOI: 10.1172/JCI46110. View

Hu H, Li Y, Zhou Q, Ao Y, Yu C, Wan Y . Redox-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugate for Tumor Targeted Drug Delivery. ACS Appl Mater Interfaces. 2016; 8(45):30833-30844. DOI: 10.1021/acsami.6b11932. View

Nagarsheth N, Wicha M, Zou W . Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017; 17(9):559-572. PMC: 5731833. DOI: 10.1038/nri.2017.49. View

10.

Yue C, Liu P, Zheng M, Zhao P, Wang Y, Ma Y . IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials. 2013; 34(28):6853-61. DOI: 10.1016/j.biomaterials.2013.05.071. View

11.

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad O . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2013; 66:2-25. PMC: 4219254. DOI: 10.1016/j.addr.2013.11.009. View

12.

Chen Q, Hu Q, Dukhovlinova E, Chen G, Ahn S, Wang C . Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells. Adv Mater. 2019; 31(23):e1900192. PMC: 7262962. DOI: 10.1002/adma.201900192. View

13.

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

14.

Annes J, Munger J, Rifkin D . Making sense of latent TGFbeta activation. J Cell Sci. 2002; 116(Pt 2):217-24. DOI: 10.1242/jcs.00229. View

15.

Zhou Q, Li Y, Zhu Y, Yu C, Jia H, Bao B . Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018; 275:67-77. DOI: 10.1016/j.jconrel.2018.02.026. View

16.

Sun Y, Fang K, Hu X, Yang J, Jiang Z, Feng L . NIR-light-controlled G-quadruplex hydrogel for synergistically enhancing photodynamic therapy via sustained delivery of metformin and catalase-like activity in breast cancer. Mater Today Bio. 2022; 16:100375. PMC: 9379686. DOI: 10.1016/j.mtbio.2022.100375. View

17.

Noga M, Edinger D, Klager R, Wegner S, Spatz J, Wagner E . The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. Biomaterials. 2013; 34(10):2530-8. DOI: 10.1016/j.biomaterials.2012.12.025. View

18.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

19.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

20.

Hu H, Xiao C, Wu H, Li Y, Zhou Q, Tang Y . Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy. ACS Appl Mater Interfaces. 2017; 9(48):42225-42238. DOI: 10.1021/acsami.7b14796. View